

RECEIVED  
REGION 1

2008 JAN -3 AM 10: 21

NMS82

December 20, 2007

**VIA CERTIFIED MAIL**  
**RETURN RECEIPT REQUESTED**

Licensing Assistant Section  
Nuclear Materials Safety Branch  
U.S. Nuclear Regulatory Commission, Region I  
475 Allendale Road  
King of Prussia, PA 19406-1415

07-30584-01  
03035435

Re: Notice of Change of Company Name and Corporate Reorganization

Dear Sir or Madam:

The U.S. Nuclear Regulatory Commission issued the following license to Quest Pharmaceutical Services, L.L.C., a Delaware limited liability company (the "**Company**"), a copy of which is enclosed ("License"):

Materials License #07-30584-01, expiration date October 31, 2010

Notice is hereby given that the Company has changed its name from Quest Pharmaceutical Services, L.L.C. to QPS, LLC and proposes to reorganize its corporate structure as described below.

The Company has entered into a Contribution and Exchange Agreement dated November 27, 2007 (the "**Contribution and Exchange Agreement**") by and among, *inter alios*, the Company, BKCA Holdings, Inc. ("**BKCA Holdings**"), and Bio-Kinetic Clinical Applications, Inc. ("**BKCA, Inc.**"), pursuant to which the following transactions are proposed (collectively, the "**Proposed Transactions**"):

1. The Company will engage in an internal reorganization via merger (the "**QPS Merger**") so that while the ultimate ownership of the Company will not change as a result of the QPS Merger, the Company will become a wholly owned subsidiary of QPS Holdings, LLC, a newly formed Delaware limited liability company ("**QPS Holdings**").

2. Following consummation of the QPS Merger, QPS Holdings will acquire all of the membership interest of Bio-Kinetic Clinical Applications, LLC, a Delaware limited liability company (successor in-interest by merger to BKCA, Inc.) ("**BKCA, LLC**"), in exchange for the issuance to BKCA Holdings and certain shareholders of BKCA Holdings an aggregate of 27.5% of the membership interest in QPS Holdings.

B # 723520 v.1

141537

NMSS/RGN1 MATERIALS-002

3. With respect to the ownership of the Company, the Proposed Transactions will result in the current members of the Company changing their ultimate ownership in the Company from 100% to 72.5%.

The Proposed Transactions do not result in a transfer of control of the License as described in section 5 of NUREG-1556, vol. 15. The Proposed Transactions will have no effect on the daily operations, laboratory procedures, laboratory facilities, or key personnel of the Company. The Company will be maintaining its existing headquarters. As in the transaction described on page D-5 of NUREG-1556, vol. 15, the original licensee will retain ultimate authority, control, and responsibility for the License and the activities permitted thereunder.

If you have any questions, please do not hesitate to call Benjamin Chien at (302) 369-5111 or T. Ben Hsu at (302) 369-5157.

Sincerely,

QPS, LLC  
(f/k/a Quest Pharmaceutical Services, L.L.C.)

By:   
T. Ben Hsu, Chief Financial Officer

Enclosure

**MATERIALS LICENSE**

Pursuant to the Atomic Energy Act of 1954, as amended, the Energy Reorganization Act of 1974 (Public Law 93-438), and Title 10, Code of Federal Regulations, Chapter I, Parts 30, 31, 32, 33, 34, 35, 36, 39, 40, and 70, and in reliance on statements and representations heretofore made by the licensee, a license is hereby issued authorizing the licensee to receive, acquire, possess, and transfer byproduct, source, and special nuclear material designated below; to use such material for the purpose(s) and at the place(s) designated below; to deliver or transfer such material to persons authorized to receive it in accordance with the regulations of the applicable Part(s). This license shall be deemed to contain the conditions specified in Section 183 of the Atomic Energy Act of 1954, as amended, and is subject to all applicable rules, regulations, and orders of the Nuclear Regulatory Commission now or hereafter in effect and to any conditions specified below.

<p style="text-align: center;">Licensee</p> <p>1. Quest Pharmaceutical Services, L.L.C.</p> <p>2. Delaware Technology Park 3 Innovation Way, Suite 240 Newark, Delaware 19711</p>	<p>In accordance with the letter dated April 25, 2005,</p> <p>3. License number 07-30584-01 is amended in its entirety to read as follows:</p> <p>4. Expiration date October 31, 2010</p> <p>5. Docket No. 03035435 Reference No.</p>
---	---

6. Byproduct, source, and/or special nuclear material	7. Chemical and/or physical form	8. Maximum amount that licensee may possess at any one time under this license
A. Hydrogen 3	A. Any	A. 75 millicuries
B. Carbon 14	B. Any	B. 50 millicuries
C. Phosphorus 32	C. Any	C. 5 millicurie
D. Phosphorus 33	D. Any	D. 5 millicurie
E. Sulfur 35	E. Any	E. 5 millicurie
F. Calcium 45	F. Any	F. 4 millicuries
G. Chromium 51	G. Any	G. 5 millicuries
H. Yttrium 90	H. Any	H. 10 millicuries
I. Technetium 99m	I. Any	I. 10 millicuries
J. Iodine 125	J. Non-volatile compounds	J. 15 millicuries
K. Rhenium 188	K. Any	K. 5 millicuries

9. Authorized use:

A. through K. Research and development as defined in 10 CFR 30.4; animal studies.

**MATERIALS LICENSE  
SUPPLEMENTARY SHEET**

License Number  
07-30584-01

Docket or Reference Number  
03035435

Amendment No. 03

**CONDITIONS**

10. Licensed material may be used only at the licensee's facilities located at: Delaware Technology Park, 3 Innovation Way, Suites 211, 225 & 240, and 1 Innovation Way, Suite 200, Newark, Delaware; and Pencader Corporate Center, 110 Executive Drive, Suite 7, Newark, Delaware.
11. A. Licensed material shall be used by, or under the supervision of, Yuan-Shek Chen, Lawrence Duan, Alfred Lordi, Kumar Ramu, Helenshen, or Eric Solon.  
B. The Radiation Safety Officer for this license is Eric Solon, Ph.D.
12. Licensed material shall not be used in or on human beings.
13. Experimental animals, or the products from experimental animals, that have been administered licensed materials shall not be used for human consumption.
14. The licensee shall not use licensed material in field applications where activity is released except as provided otherwise by specific condition of this license.
15. The licensee is authorized to hold radioactive material with a physical half-life of less than or equal to 120 days for decay-in-storage before disposal in ordinary trash, provided:
  - A. Waste to be disposed of in this manner shall be held to decay a minimum of ten half-lives.
  - B. Before disposal as ordinary trash, the waste shall be surveyed at the container surface with the appropriate survey instrument set on its most sensitive scale and with no interposed shielding to determine that its radioactivity cannot be distinguished from background. All radiation labels shall be removed or obliterated.
  - C. A record of each such disposal permitted under this License Condition shall be retained for three years. The record must include the date of disposal, the date on which the byproduct material was placed in storage, the radionuclides disposed, the survey instrument used, the background dose rate, the dose rate measured at the surface of each waste container, and the name of the individual who performed the disposal.
16. The licensee is authorized to transport licensed material in accordance with the provisions of 10 CFR Part 71, "Packaging and Transportation of Radioactive Material."

**MATERIALS LICENSE  
SUPPLEMENTARY SHEET**


License Number  
07-30584-01

Docket or Reference Number  
03035435

Amendment No. 03

17. Except as specifically provided otherwise in this license, the licensee shall conduct its program in accordance with the statements, representations, and procedures contained in the documents, including any enclosures, listed below. The U.S. Nuclear Regulatory Commission's regulations shall govern unless the statements, representations, and procedures in the licensee's application and correspondence are more restrictive than the regulations.

- A. Application dated July 11, 2000
- B. Letter dated September 26, 2000
- C. Letter dated March 28, 2002
- D. Letter dated April 30, 2002
- E. Letter dated May 17, 2004
- F. Letter dated April 25, 2005, with amendments received June 7, 2005



For the U.S. Nuclear Regulatory Commission

Date June 9, 2005

*Original signed by David B. Everhart*

David B. Everhart  
Commercial and R&D Branch  
Division of Nuclear Materials Safety  
Region I  
King of Prussia, Pennsylvania 19406

732106

This is to acknowledge the receipt of your letter/application dated

12/20/2007

, and to inform you that the initial processing which includes an administrative review has been performed.

*Approved. 07-30584-01*  
There were no administrative omissions. Your application was assigned to a technical reviewer. Please note that the technical review may identify additional omissions or require additional information.

Please provide to this office within 30 days of your receipt of this card

---

A copy of your action has been forwarded to our License Fee & Accounts Receivable Branch, who will contact you separately if there is a fee issue involved.

Your action has been assigned **Mail Control Number** 141537.  
When calling to inquire about this action, please refer to this control number.  
You may call us on (610) 337-5398, or 337-5260.

NRC FORM 532 (RI)  
(6-96)

Sincerely,  
Licensing Assistance Team Leader